477 related articles for article (PubMed ID: 16565256)
1. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study.
Remuzzi G; Macia M; Ruggenenti P
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S90-7. PubMed ID: 16565256
[TBL] [Abstract][Full Text] [Related]
2. Primary prevention of renal failure in diabetic patients: the Bergamo Nephrologic Diabetes Complication Trial.
Ruggenenti P; Remuzzi G
J Hypertens Suppl; 1998 Jan; 16(1):S95-7. PubMed ID: 9534106
[TBL] [Abstract][Full Text] [Related]
3. Preventing microalbuminuria in type 2 diabetes.
Ruggenenti P; Fassi A; Ilieva AP; Bruno S; Iliev IP; Brusegan V; Rubis N; Gherardi G; Arnoldi F; Ganeva M; Ene-Iordache B; Gaspari F; Perna A; Bossi A; Trevisan R; Dodesini AR; Remuzzi G;
N Engl J Med; 2004 Nov; 351(19):1941-51. PubMed ID: 15516697
[TBL] [Abstract][Full Text] [Related]
4. Preventing microalbuminuria in patients with type 2 diabetes.
Jermendy G; Ruggenenti P
Diabetes Metab Res Rev; 2007 Feb; 23(2):100-10. PubMed ID: 17094161
[TBL] [Abstract][Full Text] [Related]
5. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial.
Ruggenenti P; Perna A; Ganeva M; Ene-Iordache B; Remuzzi G;
J Am Soc Nephrol; 2006 Dec; 17(12):3472-81. PubMed ID: 17082240
[TBL] [Abstract][Full Text] [Related]
6. The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics.
BENEDICT Group
Control Clin Trials; 2003 Aug; 24(4):442-61. PubMed ID: 12865039
[TBL] [Abstract][Full Text] [Related]
7. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
Cooper ME
J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709
[TBL] [Abstract][Full Text] [Related]
8. Losartan in diabetic nephropathy.
Perico N; Ruggenenti P; Remuzzi G
Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
[TBL] [Abstract][Full Text] [Related]
9. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
10. [What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?].
Dussol B; Berland Y
Nephrol Ther; 2006 May; 2(2):51-74. PubMed ID: 16895717
[TBL] [Abstract][Full Text] [Related]
11. Diabetic nephropathy.
Ritz E
Saudi J Kidney Dis Transpl; 2006 Dec; 17(4):481-90. PubMed ID: 17186681
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
Bakris GL; Toto RD; McCullough PA
J Hum Hypertens; 2005 Feb; 19(2):139-44. PubMed ID: 15457206
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
Hughes DB; Britton ML
Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
[TBL] [Abstract][Full Text] [Related]
14. Advances in the treatment of diabetic renal disease: focus on losartan.
Rayner B
Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
[TBL] [Abstract][Full Text] [Related]
15. [Effect of blood glucose and blood pressure control on progression of diabetic nephropathy].
Schwarz C; Oberbauer R
Wien Klin Wochenschr; 2000 Nov; 112(21):907-11. PubMed ID: 11144004
[TBL] [Abstract][Full Text] [Related]
16. Microalbuminuria: a common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes.
Donnelly R; Yeung JM; Manning G
J Hypertens Suppl; 2003 Mar; 21(1):S7-12. PubMed ID: 12769161
[TBL] [Abstract][Full Text] [Related]
17. [The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus].
Ravera M; Deferrari L; Ratto E; Vettoretti S; Parodi D; Deferrari G
Ital Heart J Suppl; 2003 Mar; 4(3):210-6. PubMed ID: 12784755
[TBL] [Abstract][Full Text] [Related]
18. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
Agha A; Bashir K; Anwar E
Nepal Med Coll J; 2007 Jun; 9(2):79-83. PubMed ID: 17899953
[TBL] [Abstract][Full Text] [Related]
19. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients.
Steinke JM; Mauer M;
Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():958-63. PubMed ID: 18806710
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency.
Tong PC; Ko GT; Chan WB; Ma RC; So WY; Lo MK; Lee KF; Ozaki R; Chow CC; Cockram CS; Chan JC
Diabetes Obes Metab; 2006 May; 8(3):342-7. PubMed ID: 16634995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
